Æ

Participate in a Clinical Trial

Thanks for your involvement!

Clinical trials are a key research tool for advancing medical knowledge and patient care. The knowledge gained will support the treatment we will provide in the years to come. Clinical trials can provide positive impacts for many patients in the future, offering benefits such as new treatments or better drug options. Through rigorous testing, evidence-based trials ensure the solutions are safe and effective before they are used in clinical practice.

Benefits of Clinical Trials

  • You may receive a new treatment for a disease or condition before it is publicly available.
  • You play a more active role in your own health care.
  • Researchers may provide you with medical care and more frequent health check-ups as part of your treatment.
  • You may have the chance to help others get better treatment for their health problems in the future.
  • You may be able to get information about support groups and resources.

If you would like to participate in any of our future research studies or would like any information on our current projects, please contact our research department at research@wdmh.on.ca.

Asthma VALIANT - Upstream Bio

Do you have asthma? This study will evaluate the effectiveness of an investigational drug for adults with severe asthma if you:

  • are 18 to 75 years old
  • have been diagnosed with asthma by a physician and suffered attacks during the past year
  • regularly take certain medications to manage asthma
This study has been reviewed by Health Canada and the FDA. 
You will receive an injection of the study treatment every 12 weeks.
There is monetary compensation for time and travel.

 To learn more, call 613-774-2420 ext. 6211.  

 

Atherosclerosis POSEIDON - NovoNordisk

The role of inflammation in atherosclerosis has been well established, and atherosclerosis is currently considered a hybrid disease between a metabolic disorder and chronic systemic inflammation. There is also evidence showing a link between systemic inflammation and risk of cardiovascular complications. C-reactive protein (CRP) has been shown to be a reliable measure of underlying systemic inflammation and a strong predictor of future cardiovascular events.

This study will use a cross-sectional approach and conduct testing in a large sample of patients to better understand the prevalence of systemic inflammation in patients with atherosclerotic cardiovascular disease or heart failure.

Heart Failure HERMES - NovoNordisk

The current study is to demonstrate the efficacy of ziltivekimab in reducing morbidity and mortality in patients with heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or HF with preserved ejection fraction (HFpEF) and systemic inflammation.

Primary inclusion criteria: Adults aged 18+ with a clinical diagnosis of heart failure (NYHA Class II-IV), and LVEF > 40%.

Asthma FLAIR - Teva

Info to come

Get Involved:

If you would like to participate in any of our future research studies or would like any information on our current projects, please contact our research department at research@wdmh.on.ca.